Table 2. Percentage of persons with reported kidney disease in the respective KDIGO risk category.
| UACR (in mg/g) | Total | ||||
|---|---|---|---|---|---|
| < 30 | 30–300 | > 300 | |||
| eGFR (in mL/min/1.73 m2) | > 90 |
1.1
(187/16 552) |
1.8
(54/2 922) |
13.5
(12/89) |
1.3 (253/19 563) |
| 60–90 |
2.3
(289/12 392) |
2.8
(71/2 497) |
11.6
(16/138) |
2.5 (376/15 027) |
|
| 30–59 |
11.8
(70/595) |
20.7
(45/217) |
46.2
(18/39) |
15.6 (133/851) |
|
| 15–29 |
50
(1/2) |
100
(2/2) |
100
(14/14) |
94.4 (17/18) |
|
| < 15 |
0
(0/1) |
– (0/0) |
100
(1/1) |
50 (1/2) |
|
| Total | 1.9 (547/29 542) |
3.1 (172/5638) |
21.7 (91/281) |
2.2 (780/35 461) |
|
Based on the subcohort with urine test data (exclusive of participants on kidney replacement therapy, N = 35 461), the table shows the percentages of participants with reported kidney disease by KDIGO risk category. Based on the baseline eGFR and UACR values collected, the NAKO participants were assigned to their respective groups. The cell colors are based on the KDIGO color scheme for the progression of kidney disease (green: low risk – red: high risk) (2). In the cells for categories G3–G5 (eGFR < 60 mL/min/1.73 m2) and A2–A3 (UACR ≥ 30 mg/g), one would expect high values for these percentages in an ideal scenario. The sometimes very low percentages, particularly in the group with an eGFR of 30–59 mL/min/1.73 m2, indicate a lack of awareness of the possible presence of CKD. eGFR, estimated glomerular filtration rate; KDIGO, Kidney Disease Improving Global Outcomes; UACR, urinary albumin-to-creatinine ratio